Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems. Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application). The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review. Authors can choose to publish gold open access in this journal.
生物制药研究统计《生物制药研究中的统计学》(SBR),发表文章,重点关注生物制药行业研究人员和应用统计学家的需求;医学、兽医学、公共卫生和药学院的学术生物统计学家;在管理机构(例如,美国食品药品监督管理局及其在其他国家的对应机构);统计学家有兴趣采用本杂志介绍的方法,以自己的领域;和非统计学家,对应用统计学方法解决生物制药问题感兴趣。2生物制药研究中的统计学接受讨论适当的统计学方法和信息的论文,这些信息涉及在制药、生物制药、设备和诊断工业的研究、开发和实践的所有阶段中使用统计学。文章应该关注新的统计方法的发展,当前方法的新应用,或统计原理的创新应用,这些统计原理可以被这些学科的统计从业者使用。应用领域可能包括药物发现的统计方法,包括解决多重性、序贯试验、适应性设计等问题的论文;临床前和临床研究;基因组学和蛋白质组学;生物测定;生物标记物和替代标记物;药物历史的模型和分析,包括药物经济学、产品生命周期、临床研究中不良事件的检测和上市后风险评估;管理准则,包括术语标准化问题(例如,CDISC)、与制药实践相关的容许限度和质量标准限度以及新的药物批准方法;和毒理学研究中不良事件的检测。教程文章也是受欢迎的。论文应包括证明该方法有用性的证据(可能通过应用程序)。SBR编辑委员会旨在确保期刊持续提供重要、有用和及时的信息。为了实现这一目标,委员会努力吸引优秀的文章,确保每一个提交收到仔细,彻底,并迅速审查。作者可以选择发表黄金开放获取在本杂志。
Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1697738
Statistics at FDA: Reflections on the Past Six Years
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1571322
Borrowing From Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical Guidelines
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1497533
Integration of Pharmacometric and Statistical Analyses Using Clinical Trial Simulations to Enhance Quantitative Decision Making in Clinical Drug Development
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1560361
Hierarchical Testing of a Primary and a Secondary Endpoint in a Group Sequential Design With Different Information Times
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1546613
A Practical Application of Data Mining Methods to Build Predictive Models for Autism Spectrum Disorder Based on Biosensor Data From Janssen Autism Knowledge Engine (JAKE®)
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1527247
Difference in Restricted Mean Survival Time: Small Sample Distribution and Asymptotic Relative Efficiency
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1527249
Practical Considerations for Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1560360
Simulation Practices for Adaptive Trial Designs in Drug and Device Development
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1560359
Feature Selection With Weighted Importance Index in an Autism Spectrum Disorder Study
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1537886
Introduction to the 2019 special issue on Nonclinical Statistics
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1605925
Homogeneity Test of Ratio of Two Proportions in Stratified Bilateral Data
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1506359
Using Adaptive Designs to Avoid Selecting the Wrong Arms in Multiarm Comparative Effectiveness Trials
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1610044
Opportunities and Challenges for Statisticians in Advanced Pharmaceutical Manufacturing
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1546611
Univariate Versus Multivariate Surrogates in the Single-Trial Setting
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1575276
Familywise Error Rate Controlling Procedures for Discrete Data
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/10807039.2017.1381831
Baseline-Covariate Adjusted Confidence Interval for Proportional Difference Between Two Treatment Groups in Clinical Trials
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1566087
A Bayesian Sequential Design for Clinical Trials With Time-to-Event Outcomes
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1629996
Hierarchical Bayesian Benefit–Risk Modeling and Assessment Using Choice Based Conjoint
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1527248
General Framework for Equivalence Testing over a Range of Linear Outcomes with CMC Applications
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1470029
Exact Tests for Disease Prevalence Studies With Partially Validated Data
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1555099
Meta-Analysis of Clinical Trials With Sparse Binary Outcomes Using Zero-Inflated Binomial (ZIB) Models
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1537885
Discussion on Interchangeability and Adaptation in Biosimilar Development
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1559223
Statistical Applications for Chemistry, Manufacturing and Control (CMC) in the Pharmaceutical Industry
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1605265
Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1654911
A Bayesian Framework Allowing Incorporation of Retrospective Information in Prospective Diagnostic Biomarker-Validation Designs
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1574489
Permutation and Bootstrap Testing for the Sequential Parallel Comparison Design
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1549095
Incorporating Biomarkers to Improve Statistical Power of Immunotherapeutic Neoadjuvant Clinical Trials in Patients with Triple-Negative Breast Cancer
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1518259
Bayesian Estimation of Agreement of Biomarkers in Early Drug Development
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1537887
Guest Editors’ Note
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1561510
Commentary on “Statistics at FDA: Reflections on the Past Six Years”
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1554505
Analysis and Design of Clinical Trials Using Additive Hazards Survival Endpoints
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1575278
Multivariate Mixed-Effects Kinetic Models for Multiple Correlated Quality Attributes From Accelerated Stability Studies
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1555097
Notes on Interval Estimation Under the AB/BA Design in Multicenter Trials With Binary Responses
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1592772
Considering Over-Dispersion in the Sample Size Calculation for Clinical Trials With Repeated Count Measurements
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1575277
Editorial Collaborators
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1572398
Two-Arm Comparisons in Two-Stage Designs for Stratified Randomized Phase II Trials
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1573701
Editorial Collaborators
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1681216
Commentary on “Statistics at FDA: Reflections on the Past Six Years”
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1562369
“Exact and approximate power and sample size calculations for analysis of covariance in randomized clinical trials with or without stratification” by Yongqiang Tang
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1707110
Regulatory Experience of Qualifying Total Kidney Volume as a Prognostic Biomarker for Clinical Trial Enrichment
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1584913
Commentary on “Statistics at FDA: Reflections on the Past Six Years”
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1554506
A Clinical Trial Design With Covariate-Adjusted Response-Adaptive Randomization Using Superiority Confidence of Treatments
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2019.1647279
On Analysis of Changes in Rates and Averaged Correlated Rates
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1555098
Regression Analysis of Fold-Increase Endpoints Using a Distributional Approach for Paired Interval-Censored Antibody Data
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1473794
Interval Estimations for Variance Components: A Review and Implementations
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1512896
Statistically Based Release Testing Alternatives for Uniformity of Dosage Units
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1543132
Commentary on “Statistics at FDA: Reflections on the Past Six Years”
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1561509
Efficient Computing for One and Two Variance Components Parametric Tolerance Interval Testing
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1447994
“Step-Down Parametric Procedures for Testing Correlated Endpoints in a Group-Sequential Trial” by Yiyong Fu
来源期刊:Statistics in Biopharmaceutical ResearchDOI:10.1080/19466315.2018.1529614